Financial Disclosure

Castle Biosciences Study: TissueCypher Test Alters Care 90% of Time

Image
Castle Biosciences Study: TissueCypher Test Alters Care 90% of Time

Friendswood, Texas – September 28, 2026 -- Castle Biosciences, Inc. (Nasdaq: CSTL) said a new peer-reviewed study found its TissueCypher Barrett's Esophagus Test prompted clinicians to change management recommendations in 90% of cases involving patients with non-dysplastic Barrett's esophagus (NDBE).

The case series, published in Foregut: The Journal of the American Foregut Society, evaluated 30 NDBE patients tested as part of clinical care at Keck Medical Center of the University of Southern California (USC).

Test reclassifies risk within a population considered uniformly low-risk

TissueCypher classified 17% of the 30 patients as intermediate or high risk for progression to high-grade dysplasia or esophageal adenocarcinoma within five years, while 83% were confirmed low risk. All patients had received the same NDBE diagnosis prior to testing.

Brixmor, Everview and ADIA to Acquire Slate Grocery REIT for $2.34B

Image
Brixmor, Everview and ADIA to Acquire Slate Grocery REIT for $2.34B

New York – September 28, 2026 -- Brixmor Property Group Inc. (NYSE: BRX) and Everview Partners have entered definitive agreements to acquire Slate Grocery REIT in a transaction valued at $2.34 billion, splitting the portfolio between a wholly owned Brixmor acquisition and a newly formed joint venture backed by a subsidiary of the Abu Dhabi Investment Authority.

Brixmor takes wholly owned stake in 23 centers for $636 million

Brixmor will directly acquire 23 grocery-anchored shopping centers totaling approximately three million square feet for $636 million, gaining a 100% interest in 22 assets and a 50% stake in one. The portfolio is 96% leased and sits entirely within Brixmor's existing footprint, concentrated in Florida, Georgia and the Carolinas, with anchors including Publix, Harris Teeter and Kroger.

Sixty Degree Capital Portfolio Delivers Record SpaceX, Biotech IPOs in 2026

Image
Sixty Degree Capital Portfolio Delivers Record SpaceX, Biotech IPOs in 2026

Toronto – September 28, 2026 -- Sixty Degree Capital (SDC) saw five portfolio companies complete initial public offerings in 2026, including the largest IPO in history and the largest biotech IPO on record. SpaceX, Parabilis Medicines, Cerebras, HawkEye 360 and Lime each began trading on U.S. exchanges between May and July, while GrubMarket has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission.

SpaceX offering reaches approximately US$75 billion, the largest IPO ever recorded

SpaceX's public listing totaled roughly US$75 billion, according to the Toronto-based venture capital firm, marking the largest IPO in history. The offering anchors a wave of 2026 public-market exits across SDC's technology and healthcare portfolio.

GTCR Acquires Tactacam From Bertram Capital, Founders Retain Stake

Image
GTCR Acquires Tactacam From Bertram Capital, Founders Retain Stake

Chicago – September 28, 2026 -- GTCR has closed its acquisition of Tactacam, a cellular-connected camera provider serving more than one million subscribers, buying the company from Bertram Capital and its founders in a deal with undisclosed terms.

Founders retain ownership as CEO stays on to lead the business

Jeff Peel, Tactacam's CEO and co-founder, will continue leading the Company and retain significant ownership alongside co-founder Ben Thorud. Peel said the partnership with GTCR will support continued investment in the Reveal and Defend product lines while preserving the company's customer-focused approach.

MOYOM Biotech Lands Cathay Capital Funding for Global Expansion

Image
MOYOM Biotech Lands Cathay Capital Funding for Global Expansion

Shanghai – – September 28, 2026 -- MOYOM Biotech, a Chinese developer of regenerative aesthetic biomaterials, has secured a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to fund international expansion of its flagship CaHA-based implant brand Aphranel®.

Cathay Capital Fund Backed by L'Oréal Targets Beauty and Skin Science Innovation

The investment vehicle was jointly established by Cathay Capital, L'Oréal and the Shanghai Jing'an District Government. Cathay Capital's broader portfolio includes Moonshot AI (Kimi), autonomous driving firm Momenta, U.S. fintech Chime, digital asset platform Ledger, delivery platform Glovo and AI biotech company Owkin.

Infrastructure Capital Raises Distributions Across Four Income ETFs

Image
Infrastructure Capital Raises Distributions Across Four Income ETFs

New York – – September 28, 2026 -- Infrastructure Capital Advisors, LLC has increased monthly distributions across four exchange-traded funds, with its newest fund, the Nasdaq Option Income ETF (QVOL), raising its payout by $0.05 to $1.09 per share.

QVOL lifts monthly distribution to $1.09 per share, an annualized $13.08

The increase moves QVOL's per-share payout from $1.04 to $1.09, translating to $13.08 on an annualized basis. The fund targets an annualized distribution rate of between 12% and 15%, generated through call-option premiums and dividends from its equity holdings tied to the Nasdaq. Infrastructure Capital cautioned that the target range does not equate to a guaranteed yield or total return, and that distributions may include a portion classified as return of capital.

SOLA Japan Wins ¥6B AMED Grant for ALS Gene Therapy SOL-257

Tokyo – September 28, 2026 -- SOLA Biosciences Japan GK has secured a grant of approximately 6 billion yen over five years from Japan's Agency for Medical Research and Development (AMED) to advance SOL-257, a gene therapy candidate targeting the TDP-43 protein implicated in amyotrophic lateral sclerosis (ALS). The award, granted under AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, was announced June 5, 2026, and positions SOLA Japan as the company's central development hub for the program.

AMED grant targets a pathology present in 97% of ALS cases

SOL-257 is designed to restore the structure and function of misfolded TDP-43, a protein that becomes mislocalized and aggregated in motor neurons in roughly 97% of ALS cases, according to SOLA. The company describes SOL-257 as a potentially first-in-class, disease-modifying gene therapy built on its proprietary JUMP70 platform.

Ericsson's Treasury Stock Hits 108.5 Million Shares After Buyback Week

Stockholm – September 28, 2026 -- Telefonaktiebolaget LM Ericsson repurchased Class B shares on Nasdaq Stockholm during the week of September 21-25, 2026, lifting its total treasury stock holding to 108,518,663 Class B shares.

Ericsson advances SEK 15 billion buyback program launched in April 2026

The latest repurchases form part of Ericsson's share buyback program of up to SEK 15,000,000,000, announced on April 16, 2026. The program runs from April 23, 2026, through March 31, 2027, at the latest, and is being executed on Ericsson's behalf by Goldman Sachs Bank Europe SE.

Board plans to propose cancellation of repurchased shares at 2027 AGM

Ericsson's Board of Directors intends to propose to the 2027 Annual General Meeting that the repurchased shares be cancelled, with the exception of those retained to fulfil obligations under the company's share-related incentive programs.

STEMREGEN Ranks No. 332 on Inc. 5000 With 1,017% Growth

Image
STEMREGEN Ranks No. 332 on Inc. 5000 With 1,017% Growth

Whitefish, Mont. – September 26, 2026 -- STEMREGEN, a maker of science-backed stem cell supplements, has landed at No. 332 on the 2026 Inc. 5000 list after posting 1,017% revenue growth over three years, far outpacing the list's 130% median.

Company secures third straight Inc. 5000 ranking as growth trajectory accelerates

STEMREGEN previously ranked No. 265 in 2025 and No. 1,765 in 2024, marking three consecutive years on the annual list of America's fastest-growing private companies. The 2026 ranking measures revenue growth from 2022 through 2025.

Sunwest Bank Assumes $605M in Deposits in FDIC-Backed Nano Banc Deal

Image
Sunwest Bank Assumes $605M in Deposits in FDIC-Backed Nano Banc Deal

Irvine, Calif. – September 26, 2026 -- Sunwest Bank has acquired Nano Banc of Irvine, California, in an FDIC-assisted transaction that transfers approximately $605 million in deposits and $227 million in loans to the Sandy, Utah-based lender.

Regulators shut Nano Banc on September 25 before handing control to Sunwest

California's Department of Financial Protection and Innovation closed Nano Banc on Friday, September 25, placing it into FDIC receivership. The FDIC then entered an agreement with Sunwest Bank to acquire substantially all of Nano Banc's deposits and a portion of its assets, including the $605 million deposit book and $227 million loan portfolio.